A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
- Conditions
- Heart FailureSystemic Inflammation
- Interventions
- Drug: Placebo
- Registration Number
- NCT06200207
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 680
-
Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2 milligrams per liter (mg/L) at screening (visit 1)
-
Disease specific - cardiovascular:
-
N-terminal-pro-brain natriuretic peptide (NT-proBNP) greater than or equal to 225 picograms per milliliter (pg/mL) (375 pg/mL for participants with atrial fibrillation/flutter) at screening
-
Diagnosis of heart failure (New York heart association (NYHA) Class II-III)
-
Left ventricular ejection fraction (LVEF) greater than 40 percent documented by echocardiography within 12 months prior to or at screening (visit 1). The LVEF must be documented in medical records and the most recent measurement must be used to determine eligibility with no interim event signalling potential deterioration in ejection fraction (example myocardial infarction (MI) or heart failure (HF) hospitalisation)
-
Structural heart disease and/or functional heart disease documented by echocardiography within 12 months prior to or at screening (visit 1) showing at least one of the following:
- Left atrial (LA) volume index greater than 34 milliliter per square meter (mL/m^2)
- LA diameter greater than or equal to 3.8 centimeter (cm)
- LA length greater than or equal to 5.0 cm
- LA area greater than or equal to 20 square centimeter (cm^2)
- LA volume greater than or equal to 55 milliliter (mL)
- Intraventricular septal thickness greater than or equal to 1.1 cm
- Posterior wall thickness greater than or equal to 1.1 cm
- LV mass index greater than or equal to 115 gram per square meter (g/m^2) in men or greater than or equal to 95 g/m^2 in women
h) E/e' (mean septal and lateral) greater than or equal to 10 i) e' (mean septal and lateral) less than 9 centimeter per second (cm/s)
-
No heart failure hospitalisations or urgent heart failure visits between screening and randomisation
-
Able to perform the 6-minute walk test (6MWT) at screening with a minimum distance of 100 metres
-
Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score lesser than 80 at screening
- Medical conditions - cardiovascular:
- Myocardial infarction, stroke, unstable angina pectoris, transient ischaemic attack, or heart failure hospitalisation within 30 days prior to screening (visit 1)
- Systolic blood pressure greater than or equal to 180 millimeters of mercury (mmHg) at screening (visit 1). If the systolic blood pressure is 160-179 mmHg, the patient should be receiving greater than or equal to 3 antihypertensive drugs
- Heart rate above 110 or below 40 beats per minute as evaluated on the Electrocardiogram (ECG) performed at screening (visit 1)
- Planned coronary, carotid or peripheral artery revascularisation known during the screening period (visit 1)
- Planned cardiac device or atrial flutter/atrial fibrillation ablation procedure known during the screening period (visit 1)
- Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2)
- Heart failure due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, uncorrected more than moderate primary valve disease
- Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including chronic obstructive pulmonary disease (COPD)
- Any other condition judged by the investigator that could account for heart failure symptoms and signs (e.g., anaemia, hypothyroidism)
- Medical conditions - infections/immunosuppression:
- Clinical evidence of, or suspicion of, active infection at the discretion of the investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Participants will receive placebo matched to ziltivekimab administered s.c. once-monthly and added to standard of care for 12 months. Ziltivekimab Ziltivekimab Participants will receive ziltivekimab administered subcutaneously (s.c.) once-monthly and added to standard of care for 12 months.
- Primary Outcome Measures
Name Time Method Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (KCCQ-CSS) From randomisation (month 0) to end-of-treatment (month 12) Measured as score (score on scale; range; 0-100). The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.
- Secondary Outcome Measures
Name Time Method Participants improving 5 points or more in KCCQ-CSS (yes/no) From randomisation (month 0) to end-of-treatment (month 12) Measured as count of participants. The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.
Change in subscales of KCCQ (total symptom score, physical limitations score, social limitations score, and health-related quality of life) From randomisation (month 0) to end-of-treatment (month 12) Measured as score (score on scale; range 0-100). The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.
Change in six-minute walk distance (6MWD) From randomisation (month 0) to end-of-treatment (month 12) Measured in meters.
Change in N-terminal-pro-brain natriuretic peptide (NT-proBNP) From randomisation (month 0) to end-of-treatment (month 12) Measured as ratio to baseline.
Change in eGFR (CKD-EPI) From randomisation (month 0) to end-of-treatment (month 12) eGFR (CKD-EPI) is estimated glomerular filtration rate chronic kidney disease - epidemiology collaboration. Measured in milliliter per minute per 1.73 square meter (ml/min/1.73\^2).
Participant achieving threshold for clinically meaningful within-participant change in KCCQ CSS (yes/no) From randomisation (month 0) to end-of-treatment (month 12) Measured as count of participants. The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.
Change in high-sensitivity C-reactive protein (hs-CRP) From randomisation (month 0) to end-of-treatment (month 12) Measured as ratio to baseline.
Participant achieving threshold for clinically meaningful within-participant change in 6-minute walk distance (6MWD) (yes/no) From randomisation (month 0) to end-of-treatment (month 12) Measured as count of participants.
Participants improving 10 points or more in KCCQ-CSS (yes/no) From randomisation (month 0) to end-of-treatment (month 12) Measured as count of participants. The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.
Participants experiencing improvement in New York heart association (NYHA) Class (yes/no) From randomisation (month 0) to end-of-treatment (month 12) Measured as count of participants. The New York Heart Association (NYHA) classification provides a simple way of classifying the extent of heart failure (HF). It classifies patients in one of four categories based on their limitations during physical activity - Class I: Participant with cardiac disease but without resulting limitations of physical activity, Class II: Participants with cardiac disease resulting in slight limitation of physical activity, Class III: Participants with cardiac disease resulting in marked limitation of physical activity, Class IV: Participants with cardiac disease resulting in inability to carry on any physical activity without discomfort.
Trial Locations
- Locations (197)
Hospital Raja Perempuan Zainab II
🇲🇾Kota Bharu, Kelantan, Malaysia
MHAT Heart and Brain
🇧🇬Pleven, Bulgaria
"UMHAT "Sveti Georgi" EAD
🇧🇬Plovdiv, Bulgaria
Advanced Cardiovascular, LLC
🇺🇸Alexander City, Alabama, United States
Eastern Shore Rsrch Inst, LLC
🇺🇸Fairhope, Alabama, United States
Cardiology & Medicine Clinic
🇺🇸Little Rock, Arkansas, United States
Valley Clinical Trials, Inc.
🇺🇸Northridge, California, United States
UCI Health
🇺🇸Orange, California, United States
South California Heart Spc
🇺🇸Pasadena, California, United States
Clearwater Cardiovascular Consultants
🇺🇸Largo, Florida, United States
Ocala Cardiovascular Research
🇺🇸Ocala, Florida, United States
Ormond Beach Clinical Research
🇺🇸Ormond Beach, Florida, United States
St Johns Ctr Clin Rsch-St. Aug
🇺🇸Saint Augustine, Florida, United States
GA Arrhythmia Cons & Rsch Inst
🇺🇸Macon, Georgia, United States
Velocity Clin Rsrch - Savannah
🇺🇸Savannah, Georgia, United States
Chicago Medical Research LLC
🇺🇸Hazel Crest, Illinois, United States
UofL Health Care Outpatient
🇺🇸Louisville, Kentucky, United States
Maryland Cardiovascular Specialists - Baltimore
🇺🇸Baltimore, Maryland, United States
MD Medical Research
🇺🇸Oxon Hill, Maryland, United States
Cardio and Vascular Assoc-CAVA
🇺🇸Bloomfield Hills, Michigan, United States
Millennium Cardiology
🇺🇸Farmington Hills, Michigan, United States
Kansas City VA Medical Center
🇺🇸Kansas City, Missouri, United States
Washington University
🇺🇸Saint Louis, Missouri, United States
Renown Regional Medical Center
🇺🇸Reno, Nevada, United States
Long Island Cardiovascular Consultants PC
🇺🇸Lake Success, New York, United States
Mount Sinai Hosp at NYC
🇺🇸New York, New York, United States
Northwell Health Phys Cardio
🇺🇸Riverhead, New York, United States
University Of North Carolina At Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
AMS Cardiology
🇺🇸Horsham, Pennsylvania, United States
University of Pennsylvania Hospital
🇺🇸Philadelphia, Pennsylvania, United States
PharmaTex Research
🇺🇸Amarillo, Texas, United States
University of Texas Southwestern Medical Center
🇺🇸Dallas, Texas, United States
David Turbay, MD, PLLC
🇺🇸El Paso, Texas, United States
Private Practice Leadership LLC.
🇺🇸Katy, Texas, United States
Clinical Advancement Ctr, PLLC
🇺🇸San Antonio, Texas, United States
Sherman Clinical Research
🇺🇸Sherman, Texas, United States
Northwest Heart Center
🇺🇸Tomball, Texas, United States
Sentara Clinical Research
🇺🇸Norfolk, Virginia, United States
Virginia Commonwealth University
🇺🇸Richmond, Virginia, United States
Centro Médico CIMEL
🇦🇷Lanus Este, Buenos Aires, Argentina
Instituto de Investigaciones Clinicas Quilmes SRL
🇦🇷Buenos Aires, Argentina
CIPREC Pueyrredon
🇦🇷Buenos Aires, Argentina
Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
🇦🇷Buenos Aires, Argentina
Centro de Investigación y Prevención Cardiovascular
🇦🇷Caba, Argentina
Cardiologia Palermo_LOC#1
🇦🇷City of Buenos Aires, Argentina
Sanatorio Esperanza
🇦🇷Esperanza, Santa Fe, Argentina
Consultorio Integral de Atención al Diabético
🇦🇷Morón, Argentina
Centro Cardiovascular Salta
🇦🇷Salta, Argentina
Investigaciones Clinicas Tucuman
🇦🇷San Miguel De Tucumán, Tucumán., Argentina
The Canberra Hospital_Garran
🇦🇺Garran, Australian Capital Territory, Australia
John Hunter Hospital
🇦🇺New Lambton Heights, New South Wales, Australia
Illawarra Heart Health Centre
🇦🇺Wollongong, New South Wales, Australia
The Prince Charles Hospital
🇦🇺Brisbane, Queensland, Australia
Ballarat Base Hospital
🇦🇺Ballarat, Victoria, Australia
The Cardiologists Pty Ltd
🇦🇺Epping, Victoria, Australia
Advara HeartCare
🇦🇺Mulgrave, Victoria, Australia
Fiona Stanley Hospital Cardiology
🇦🇺Murdoch, Western Australia, Australia
MHAT "Puls" AD Cardiology Department
🇧🇬Blagoevgrad, Bulgaria
MHAT Haskovo AD
🇧🇬Haskovo, Bulgaria
"Medical Center Hera" EOOD - Sofia
🇧🇬Sofia, Bulgaria
Medical center ISUL - Tsaritsa Yoanna EOOD
🇧🇬Sofia, Bulgaria
"UMHATEM N.I. Pirogov" EAD
🇧🇬Sofia, Bulgaria
"UMHAT "Sveta Anna" Sofia" AD, Clinic of Cardiology
🇧🇬Sofia, Bulgaria
Medical Center Synexus Sofia
🇧🇬Sofia, Bulgaria
University of Calgary_Calgary
🇨🇦Calgary, Alberta, Canada
Cambridge Cardiac Care Centre
🇨🇦Cambridge, Ontario, Canada
Saul Vizel Pro. Med. Corp
🇨🇦Cambridge, Ontario, Canada
Corcare Cardiovascular Research
🇨🇦Scarborough, Ontario, Canada
Diabetes Heart Research Centre
🇨🇦Toronto, Ontario, Canada
CPS Research
🇨🇦Waterloo, Ontario, Canada
Clinical Research Solutions Inc.
🇨🇦Waterloo, Ontario, Canada
Institut de Cardiologie de Montreal
🇨🇦Montreal, Quebec, Canada
Montreal General Hospital
🇨🇦Montreal, Quebec, Canada
CHU de Quebec-Uni Laval-Hotel
🇨🇦Quebec, Canada
Innera s.r.o.
🇨🇿Benešov, Czechia
Kardiologicka ambulance Brno s.r.o.
🇨🇿Brno, Czechia
Vojenská nemocnice Brno p.o.
🇨🇿Brno, Czechia
Ordinace pro choroby srdce
🇨🇿Chomutov, Czechia
MEDICON a.s.
🇨🇿Praha 7, Czechia
Svitavska nemocnice Kardiologie
🇨🇿Svitavy, Czechia
Kardiologie Trutnov Ferkl
🇨🇿Trutnov, Czechia
Nemocnice AGEL Třinec-Podlesí a.s.
🇨🇿Třinec, Czechia
Centre Hospitalier Regional Universitaire de Tours-Hopital Trousseau
🇫🇷Chambray Les Tours, France
Centre Hospitalier Universitaire de Poitiers
🇫🇷Poitiers, France
Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou
🇫🇷Rennes, France
Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle
🇫🇷Rouen cedex, France
Centre Hospitalier Intercommunal Toulon La Seine-Sur-Mer - Hopital Sainte Musse
🇫🇷Toulon, France
Polyclinique Vauban
🇫🇷Valenciennes, France
Chru de Nancy - Hopital Brabois
🇫🇷Vandoeuvre Les Nancy, France
Kardiologisch-Angiologische Praxis Herzzentrum Bremen
🇩🇪Bremen, Germany
Herzzentrum Dresden GmbH Universitätsklinik
🇩🇪Dresden, Germany
Zentrum fuer klinische Studien Suedbrandenburg GmbH
🇩🇪Elsterwerda, Germany
Hospitalvereinigung TH-Kath. KH St. Johann Nepomuk-Innere Med. II
🇩🇪Erfurt, Germany
MVZ CCB Frankfurt Und Main-Taunus GbR
🇩🇪Frankfurt, Germany
Medical Center - University Of Freiburg
🇩🇪Freiburg, Germany
MVZ im Altstadt-Carree Fulda GmbH - Zentrum für klinische Studien
🇩🇪Fulda, Germany
UKS - Innere Medizin III
🇩🇪Homburg, Germany
Kardiopraxis Schirmer
🇩🇪Kaiserslautern, Germany
Gesundheitscentrum Mainz (Regner / Schmitt)
🇩🇪Mainz, Germany
Alexandra General Hospital, Therapeutic Clinic
🇬🇷Athens, Attiki, Greece
Evangelismos Hospital
🇬🇷Athens, Greece
Naval Hospital of Athens
🇬🇷Athens, Greece
"Laiko" General Hospital of Athens
🇬🇷Athens, Greece
'G. Gennimatas' General Hospital of Athens
🇬🇷Athens, Greece
Konstantopouleio G.H. of Athens, "Agia Olga"
🇬🇷Athens, Greece
"Hygeia" General Hospital of Athens
🇬🇷Athens, Greece
Metropolitan General Hospital Healthcare Facilities Operation And Management Single Member S.A.
🇬🇷Athens, Greece
U.G.H of Athens "Attikon"
🇬🇷Chaidari, Athens, Greece
General Hospital of Chalkida
🇬🇷Chalkida, Greece
General Hospital of Chios "Skilitsio"
🇬🇷Chios, Greece
Univ Gen Hospital Larisa, Cardiology Medicine Clinic
🇬🇷Larissa, Greece
Sismanogleio General Hospital
🇬🇷Marousi, Greece
"AHEPA" University General Hospital of Thessaloniki
🇬🇷Thessaloniki, Greece
'Ippokrateio' General Hospital of Thessaloniki
🇬🇷Thessaloniki, Greece
Gen Hospital of Thessaloniki G.Papanikolaou,Cardiology Dpt
🇬🇷Thessaloniki, Greece
Siddhartha Medical College & Government General Hospital
🇮🇳Vijaywada, Andhra Pradesh, India
King George Hospital
🇮🇳Visakhapatnam, Andra Pradesh, India
G B Pant Institute of Postgraduate Medical Education and Research
🇮🇳New Delhi, Delhi, India
All India Institute of Medical Sciences (AIIMS)
🇮🇳New Delhi, Delhi, India
Vardhaman Mahavir Medical College & Safdarjung Hospital
🇮🇳New Delhi, Delhi, India
Sir Ganga Ram Hospital
🇮🇳New Delhi, Delhi, India
Rajiv Gandhi Super Speciality Hospital
🇮🇳New Delhi, Delhi, India
Rhythm Heart Institute
🇮🇳Vadodara, Gujarat, India
KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre
🇮🇳Belagavi, Karnataka, India
St John's Medical College Hospital
🇮🇳Bengaluru, Karnataka, India
Sri Jayadeva Institute of Cardiovascular Sciences & Research
🇮🇳Bengaluru, Karnataka, India
Manipal Hospital, Mysuru
🇮🇳Mysuru, Karnataka, India
Kasturba Medical College and Hospital, Manipal
🇮🇳Udupi, Karnataka, India
Sengupta Hospital and Research Institute
🇮🇳Nagpur, Maharashtra, India
All India Institute of Medical Sciences (AIIMS), Nagpur
🇮🇳Nagpur, Maharashtra, India
Chopda Medicare and Research Centre Pvt. Ltd.
🇮🇳Nashik, Maharashtra, India
Vijan Hospital & Research Centre
🇮🇳Nashik, Maharashtra, India
Villoo Poonawalla Memorial Hospital
🇮🇳Pune, Maharashtra, India
All India Institute of Medical Sciences (AIIMS), Bhubaneswar
🇮🇳Bhubaneswar, Odisha, India
S.P. Medical College & Associated Group of Hospitals
🇮🇳Bikaner, Rajasthan, India
Guru Nanak CARE Hospitals
🇮🇳Hyderabad, Telangana, India
Malla Reddy Narayana Multispeciality Hospital
🇮🇳Hyderabad, Telangana, India
Ganesh Shankar Vidyarthe Memorial (GSVM) Medical College
🇮🇳Kanpur, Uttar Pradesh, India
Dr. Ram Manohar Lohia Institute of Medical Sciences
🇮🇳Lucknow, Uttar Pradesh, India
Sanjay Gandhi Postgraduate Institute of Medical Sciences
🇮🇳Lucknow, Uttar Pradesh, India
Zanamed Medical Clinic Sp. z o.o.
🇵🇱Lublin, Poland
Jawaharlal Nehru Medical College and Hospital
🇮🇳Aligarh, Utter Pradesh, India
B M Birla Heart Research Centre
🇮🇳Kolkata, West Bengal, India
Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)
🇮🇳Puducherry, India
Hospital Sultanah Aminah
🇲🇾Johor Bahru, Johor, Malaysia
Hospital da Luz
🇵🇹Lisboa, Portugal
Hospital Sultanah Bahiyah
🇲🇾Alor Setar, Kedah, Malaysia
Hospital Tengku Ampuan Afzan
🇲🇾Kuantan, Pahang, Malaysia
Hospital Raja Permaisuri Bainun Ipoh
🇲🇾Ipoh, Perak, Malaysia
Hospital Serdang
🇲🇾Kajang, Selangor, Malaysia
University Malaya Medical Centre
🇲🇾Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
Pratia S.A.
🇵🇱Jelenia Góra, Dolnoslaskie, Poland
4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu
🇵🇱Wroclaw, Dolnoslaskie, Poland
Centrum Medyczne Intercor Sp. z o.o.
🇵🇱Bydgoszcz, Kujawsko-Pomorskie, Poland
Kardio Life
🇵🇱Włocławek, Kujawsko-pomorskie, Poland
Uniwersytecki Szpital Kliniczny nr 2 Uniwersytetu Medycznego w Łodzi
🇵🇱Lodz, Lodzkie, Poland
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika
🇵🇱Lodz, Lodzkie, Poland
Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Pulawach
🇵🇱Pulawy, Lubelskie, Poland
Cardiomedicum Sp. z o.o.
🇵🇱Kraków, Malopolskie, Poland
Formed 2 Sp. z o.o.
🇵🇱Oswiecim, Malopolskie, Poland
Prywatna Praktyka Lekarska Anna Chudoba
🇵🇱Żyrardów, Masovian, Poland
Linden sp. z o.o. sp. k.
🇵🇱Kraków, Małopolskie, Poland
Uniwersytecki Szpital Kliniczny w Bialymstoku
🇵🇱Białystok, Podlaskie, Poland
Ind. Prak. Lek. w dziedz. Kardiologii lek. med. K. Cymerman
🇵🇱Gdynia, Pomorskie, Poland
Szpitale Pomorskie Sp. z o.o.
🇵🇱Gdynia, Poland
American Heart of Poland S.A.
🇵🇱Tychy, Poland
10 Wojskowy Szpital Kliniczny z Polikliniką - Samodzielny Publiczny Zakład Opieki Zdrowotnej w Bydgoszczy
🇵🇱Bydgoszcz, Poland
Trialmed Sp. z o. o.
🇵🇱Piotrków Trybunalski, Poland
Uniwersytecki Szpital Kliniczny W Poznaniu
🇵🇱Poznan, Poland
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
🇵🇱Warszawa, Poland
CHTâmega e Sousa - Hospital Padre Américo
🇵🇹Guilhufe - Penafiel, Portugal
Centro Hospitalar Lisboa Norte
🇵🇹Lisboa, Portugal
CHLO, EPE - Hospital São Francisco Xavier
🇵🇹Lisbon, Portugal
Centro Hospitalar de Setubal
🇵🇹Setubal, Portugal
Hospital Nisa Sevilla Aljarafe
🇪🇸Castilleja De La Cuesta. Sevilla, Andalucia, Spain
Hospital Universitario de Salamanca
🇪🇸Salamanca, Castilla Y León, Spain
Hospital Universitario Puerta de Hierro Majadahonda
🇪🇸Majadahonda, Madrid, Spain
Hospital Gregorio Marañón
🇪🇸Madrid, Spain
Hospital Ramón y Cajal
🇪🇸Madrid, Spain
Hospital Virgen del Camino - Sanlúcar de Barrameda
🇪🇸Sanlúcar de Barrameda, Spain
Complejo Hospitalario Universitario de Santiago
🇪🇸Santiago de Compostela, Spain
Clínica Nuevas Tecnologías en Diabetes y Endocrinología
🇪🇸Sevilla, Spain
Fundación para la Investigación del Hospital Clínico de Valencia (INCLIVA)
🇪🇸Valencia, Spain
Eskisehir Osmangazi University Sağlık Uygulama ve Arastirma
🇹🇷Eskisehir, Odunpazari, Turkey
T.C. Saglık Bakanlıgı Adana Sehir Egitim ve Arastirma Hastan
🇹🇷Adana, Turkey
Afyonkarahisar Health Sciences University
🇹🇷Afyon, Turkey
Ankara Sehir Hastanesi Cardiology
🇹🇷Ankara, Turkey
Bursa Sehir Hastanesi Cardiology
🇹🇷Bursa, Turkey
Trakya University
🇹🇷Edirne, Turkey
Basaksehir Cam ve Sakura Sehir Hastanesi
🇹🇷Istanbul, Turkey
Erciyes University Cardiology
🇹🇷Kayseri, Turkey
Kocaeli Universitesi Tip Fakultesi Hastanesi
🇹🇷Kocaeli, Turkey
Raigmore Hospital
🇬🇧Inverness, Highland, United Kingdom
St. Richards Hospital
🇬🇧Chichester, West Sussex, United Kingdom
FutureMeds
🇬🇧Birmingham, United Kingdom
Ninewells Hospital
🇬🇧Dundee, United Kingdom
Peterborough City Hospital
🇬🇧Peterborough, United Kingdom